Lauren A Dalvin1, Fernando C Fervenza2, Sanjeev Sethi3, Jose S Pulido4. 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. 2. Department of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. 3. Department of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota. 4. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota; Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: pulido.jose@mayo.edu.
Abstract
PURPOSE: Membranoproliferative glomerulonephritis (MPGN) recently was reclassified to reflect the underlying cause as a complement-mediated and immune complex-mediated disease. This classification is based on renal biopsy immunofluorescence examination, making the former electron-microscopy classification obsolete. In this report, we describe related eye findings in patients with MPGN based on the new classification. DESIGN: Retrospective case series. PARTICIPANTS: All Mayo Clinic Rochester patients with pathology-confirmed complement- and immune complex-mediated MPGN who had available ophthalmology records from 1997 through 2014 were included in this study. METHODS: The medical and pathologic records of patients with MPGN and eye examination results were reviewed from years 1997 through 2014. MAIN OUTCOME MEASURES: The number of patients and the number of eyes with MPGN-related pathologic features were examined. Visual acuity also was considered. RESULTS: There were 23 patients with complement-mediated MPGN and available eye examination results. Of these, 9 patients (39%) and 17 eyes (37%) had retinal pathologic features that likely were related to the same underlying pathophysiologic process as their renal disease. Five patients (22%) and 6 eyes (13%) had significant vision loss. There were 23 patients with immune complex-mediated MPGN and available eye examination results. Only 2 (9%) of these patients (4 eyes) had retinal pathologic features that potentially could be related to the same underlying pathophysiologic process as their renal disease, and neither had vision loss. CONCLUSIONS: Retinal abnormalities are more prominent among patients with complement-mediated MPGN when compared with patients with immune complex-mediated MPGN. It is critical for ophthalmologists to recognize the updated MPGN classification system, and all patients with complement-mediated MPGN require screening eye examinations.
PURPOSE:Membranoproliferative glomerulonephritis (MPGN) recently was reclassified to reflect the underlying cause as a complement-mediated and immune complex-mediated disease. This classification is based on renal biopsy immunofluorescence examination, making the former electron-microscopy classification obsolete. In this report, we describe related eye findings in patients with MPGN based on the new classification. DESIGN: Retrospective case series. PARTICIPANTS: All Mayo Clinic Rochester patients with pathology-confirmed complement- and immune complex-mediated MPGN who had available ophthalmology records from 1997 through 2014 were included in this study. METHODS: The medical and pathologic records of patients with MPGN and eye examination results were reviewed from years 1997 through 2014. MAIN OUTCOME MEASURES: The number of patients and the number of eyes with MPGN-related pathologic features were examined. Visual acuity also was considered. RESULTS: There were 23 patients with complement-mediated MPGN and available eye examination results. Of these, 9 patients (39%) and 17 eyes (37%) had retinal pathologic features that likely were related to the same underlying pathophysiologic process as their renal disease. Five patients (22%) and 6 eyes (13%) had significant vision loss. There were 23 patients with immune complex-mediated MPGN and available eye examination results. Only 2 (9%) of these patients (4 eyes) had retinal pathologic features that potentially could be related to the same underlying pathophysiologic process as their renal disease, and neither had vision loss. CONCLUSIONS:Retinal abnormalities are more prominent among patients with complement-mediated MPGN when compared with patients with immune complex-mediated MPGN. It is critical for ophthalmologists to recognize the updated MPGN classification system, and all patients with complement-mediated MPGN require screening eye examinations.
Authors: Ahmad M Mansour; Luiz H Lima; J Fernando Arevalo; Miguel Hage Amaro; Virginia Lozano; Alaa Bou Ghannam; Errol W Chan Journal: Am J Ophthalmol Case Rep Date: 2017-06-22
Authors: Elon H C van Dijk; Darius Soonawala; Vera Rooth; Carel B Hoyng; Onno C Meijer; Aiko P J de Vries; Camiel J F Boon Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-10-23 Impact factor: 3.117
Authors: Pascal Bus; Jamie S Chua; Céline Q F Klessens; Malu Zandbergen; Ron Wolterbeek; Cees van Kooten; Leendert A Trouw; Jan A Bruijn; Hans J Baelde Journal: Kidney Int Rep Date: 2017-10-16